GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aravive Inc (STU:VE11) » Definitions » Float Percentage Of Total Shares Outstanding

Aravive (STU:VE11) Float Percentage Of Total Shares Outstanding

: 61.57% (As of Today)
View and export this data going back to 2017. Start your Free Trial

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Aravive's float shares is 45.29 Mil. Aravive's total shares outstanding is 73.56 Mil. Aravive's float percentage of total shares outstanding is 61.57%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Aravive's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Aravive's Institutional Ownership is 2.89%.

Aravive Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Aravive's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=45.29/73.56
=61.57%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aravive (STU:VE11) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aravive Inc (STU:VE11) » Definitions » Float Percentage Of Total Shares Outstanding
Comparable Companies
BNTC VYNE ONVO ENZN CMRA INTI GRTX VIRI BRTX TMBR OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
ARAV:USA VE11:Germany
Address
3730 Kirby Drive, River Oaks Tower, Suite 1200, Houston, TX, USA, 77098
Website
https://www.aravive.com
Aravive Inc is a clinical-stage biopharmaceutical company. It focuses on developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. The company pipeline product Batiraxcept (formerly AVB-500) which is an ultra-high affinity decoy protein that binds to GAS6 and thereby prevents AXL signaling to inhibit metastasis and tumor growth and restore sensitivity to anti-cancer agents. Batiraxcept is currently being evaluated in multiple clinical trials.

Aravive (STU:VE11) Headlines

No Headlines